NDC product
Mavyret
NDC 0074-2600 · AbbVie Inc.
Key facts
| Product NDC | 0074-2600 |
|---|---|
| Proprietary name | Mavyret |
| Nonproprietary name | Glecaprevir and Pibrentasvir |
| Substances | PIBRENTASVIR, GLECAPREVIR |
| Dosage form | PELLET |
| Route | ORAL |
| Labeler | AbbVie Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA215110 |
| Pharmacologic classes | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], HCV NS3/4A Protease Inhibitors [MoA], Hepatitis C Virus NS3/4A Protease Inhibitor [EPC], Hepatitis C Virus NS5A Inhibitor [EPC] and 4 more |
| Marketing start | Jun 10, 2021 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: